+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 30Years +
All Genders
ID07839793

Flexilev Treatment Using OraFID Device and Levilog App for Parkinsons Disease A 12-Week Patient Experience Study

Led by Navamedic AB · Updated on 2026-09-24

58

Participants Needed

5

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating Flexilev, a Parkinsons disease medicine made of small dissolvable tablets containing low doses of levodopa and carbidopa. The study focuses on how well patients accept and stick with this treatment when delivered using the OraFID dosing device, which accurately dispenses the right number of tablets, and the optional Levilog app that reminds patients to take their doses and records usage. This is an open-label, phase 4 study involving patients with idiopathic Parkinsons disease that responds to levodopa. Participants first undergo a run-in period of up to two weeks where their current treatment is recorded and eligibility is assessed. Eligible patients then switch to Flexilev delivered via the OraFID device and receive individualized dosing based on their doctors evaluation. Other daytime levodopa medications are stopped, though slow-release levodopa at night is allowed. After starting treatment, patients receive follow-up phone calls at weeks 1, 4, and 8, and an in-person visit at week 12, with dose adjustments allowed as needed during the 12-week treatment period. During the study, participants acceptability and satisfaction with the OraFID device and the Levilog app are assessed through questionnaires. Researchers also monitor treatment compliance, safety, changes in motor and non-motor symptoms, depression, quality of life, sleep quality, and disease severity. The total participation lasts up to 12 weeks after the run-in period, with regular phone and in-person assessments to track treatment experience and effects.

CONDITIONS

Brief Title

A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients

Research Team

D

Dag Nyholm, Professor

J

Jack Spira, MD. Ph.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here